There have been few studies of antifungal agents in pregnant women. The U.S. Food and Drug Administration (FDA) has classified most systemic antifungals as belonging in category C. This means animal studies have shown a risk to animal fetuses, but the drug has not been adequately studied in humans. In general, systemic antifungal medications should be prescribed for pregnant women only if the benefit of using such drugs outweighs the potential risk to the fetus. Many antifungal medications are excreted in breast milk, and therefore should not be used by nursing mothers.

Most topical antifungals are classified by the FDA as belonging to category B. This means that either animal studies have shown no risk to an animal fetus, or human studies have shown no risk to a human fetus.